Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care

Completed · Phase 4

Conditions studied: Alcohol Dependence

In brief

The proposed study is a pragmatic, randomized, open-label clinical trial of 24 weeks of XR-NTX vs. O-NTX using a COMBINE-adapted Medical Management primary care treatment model. 237 adults \>18yo with alcohol dependence will be recruited from the community into treatment in public sector primary care settings. The primary outcome which powers this study is a dichotomous good clinical outcome defined by abstinence or moderate drinking, and as measured by the Timeline Follow-back and analyzed using an intention-to-treat approach among all randomized participants. Secondary outcomes include the incremental cost effectiveness of the two arms, differences between arms by continuous measures of alcohol intake (drinks/day, % days abstinent, time to first heavy drinking day, bio-markers), and the exploratory analysis of factors possibly associated with effectiveness, including gender, prior treatment abstinence, and mu opioid receptor (OPRM1) genotypes. Specific Aim 1: Treatment Effectiveness. To evaluate the effectiveness of extended-release naltrexone (XR-NTX) vs. oral naltrexone (O-NTX) in producing a primary good clinical outcome, defined as abstinence or moderate drinking (≤2 drinks/day, men; ≤1 drink/day,women; and ≤2 heavy drinking occasions/month), during the final 20 of 24 weeks of primary care-based Medical Management for alcohol dependence. Hypothesis: The rate of this good clinical outcome will be approximately twice as great among participants receiving XR-NTX compared with those receiving O-NTX. Specific Aim 2: Cost Effectiveness. To estimate the incremental cost effectiveness of XR-NTX vs. O-NTX,both in conjunction with primary care-based Medical Management. Hypothesis: XR-NTX treatment will be more cost effective than O-NTX. Specific Aim 3: Patient-Level Predictors of Effectiveness. To identify patient-level characteristics associated with effectiveness in both arms.

Key facts

Study ID

NCT01893827

Run by

NYU Langone Health

People needed

237

Starts

2014-06-01

Expected to finish

2018-10-03

Last updated by the study team

2020-06-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults, age ≥18 y.o.
• English- or Spanish- speaking and able to understand study procedures and provide full consent.
• DSM IV diagnosis of alcohol dependence as determined by study physician and DSM IV checklist.
• Endorses goal of abstinence, and is able to achieve alcohol abstinence without inpatient detoxification, per study physician.

You may not qualify if…

• Current opioid dependence and/or positive urine toxicology for extended opioids.
• Pregnancy or female planning conception.
• Allergy to naltrexone or the PGL XR-NTX formulation or diluent.
• Severe liver disease, liver failure, or liver function test levels greater than three times normal.
• Other severe, untreated or uncontrolled medical illness (e.g., severe heart failure or dementia).

Where it is running

• New York University School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.